DenmarkDenmark

Things are looking up for Zealand

17.12.2011

Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe, the chances that Zealand will be able to cash in on its once-daily GLP-1 receptor agonist have risen. Although no direct payments are linked to the MAA, there is a milestone payment involving completion of the full GetGoal Phase III programme expected in the first quarter of 2012. Zealand Pharma is also eligible for low double-digit royalties on worldwide sales of lixisenatide, and of any combination product that includes it. Under the agreement with Sanofi, Zealand Pharma is eligible to receive remaining milestone payments of up to €170m, covering different formulations and combinations of the compound. Submission for regulatory approval in the US is expected at the end of 2012. Sanofi is completing Phase III development of the drug as a monotherapy and as an add-on to existing diabetes type 2 treatments, preferably Sanofi’s Lantus. The actual filing is based on the Phase III GetGoal study, which comprises data from nine other studies and more than 4,300 patients

DenmarkDenmark

15.08.2011

Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...

DenmarkDenmark

12.08.2011

Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...

DenmarkDenmark

06.06.2011

Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...

DenmarkDenmark

12.04.2011

Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...

DenmarkDenmark

09.04.2011

Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

DenmarkDenmark

16.11.2010

Vedback – Danish biotech company Exiqon A/S has reported data showing a significant shortening of progression-free survival in 130 stage II colon patients expressing high levels of microRNA21 (miR-21) in stromal cells surrounding...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/1/article/things-are-looking-up-for-zealand.html

Image Gallery

Stock list

All quotes

TOP

  • THROMBOGENICS (B)22.00 EUR16.5%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CLAVIS PHARMA (N)2.18 NOK6.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • DIAGENIC (N)0.79 NOK-38.3%
  • PAION (D)3.08 EUR-18.5%

TOP

  • WILEX (D)1.04 EUR79.3%
  • CO.DON (D)3.10 EUR74.2%
  • BIOTECH PHARMACON (N)18.20 NOK56.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • BIONOR PHARMA (N)2.08 NOK-48.6%
  • DIAGENIC (N)0.79 NOK-45.9%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6041.2%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)10.75 GBP593.5%

FLOP

  • CYTOS (CH)0.15 CHF-96.5%
  • EVOCUTIS (UK)0.25 GBP-91.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

White Paper